The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Has management of locally advanced intrahepatic cholangiocarcinoma evolved with the evidence? Trends and practice patterns from the National Cancer Database.
 
Lauren E. Schleimer
Stock and Other Ownership Interests - Allakos
 
Hannah L Kalvin
No Relationships to Disclose
 
T. Peter Kingham
Honoraria - Olympus Medical Systems
Consulting or Advisory Role - Physicans' Education Resource
 
Kevin Soares
No Relationships to Disclose
 
Michael Ian D'Angelica
No Relationships to Disclose
 
Vinod P. Balachandran
Research Funding - Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Inventors on a patent application related to work on antigen cross-reactivity and on a patent application related to work on neoantigen quality modeling.
 
Jeffrey A. Drebin
Employment - American Regent (I)
Leadership - American Regent (I)
Stock and Other Ownership Interests - Alnylam; Arrowhead Pharmaceuticals; Ions Pharmaceuticals
 
Andrea Cercek
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Seagen
Patents, Royalties, Other Intellectual Property - Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Neoadjuvant PD1 blockade in mismatch repair deficient solid tumors (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Helio Health; Incyte; Ipsen; Merck Serono; Merus NV (I); Neogene Therapeutics (I); Newbridge Pharmaceuticals; Novartis (I); QED Therapeutics; Roche/Genentech; SERVIER; Tempus (I); Thetis Pharma (I); Vector Health; Yiviva
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Mithat Gonen
Travel, Accommodations, Expenses - Genentech
 
Alice Chia-Chi Wei
Honoraria - AstraZeneca Canada
Consulting or Advisory Role - Biosapien; Histosonics
Research Funding - Ipsen (Inst)
Other Relationship - BioNTech SE (Inst)
 
William R. Jarnagin
No Relationships to Disclose